The combination of a MiniMed® Veo™ Insulin Pump and Continuous Glucose Monitoring gives you better control and understanding of your glucose levels 24 hours a day. Our CONTOUR® LINK Meter automatically sends your blood glucose results data to your pump, so you don’t need to record it manually. CareLink™ personal software allows you to quickly download your data and share it with your doctor.
Successful diabetes management is not just about knowing where your glucose levels are, it’s about knowing where they’ve been and where they’re going. See real-time glucose readings and long-term trend tracking anytime you want by adding REAL-Time Continuous Glucose Monitoring (CGM) to your insulin pump. Clinical studies have shown that the use of CGM with insulin pump therapy can significantly reduce HbA1c without increasing the risk of severe hypoglycaemia4-11.
The MiniMed® Veo™ and MiniMed 640G are the only available automated insulin delivery systems with Low Glucose Suspend. If you are unable to respond to warnings alerting you to falling glucose levels, the MiniMed® Veo™ will suspend insulin delivery to prevent a severe hypoglycaemic event. Research indicates that when Low Glucose Suspend is active, the MiniMed® Veo™ significantly reduces hypoglycaemia12,13.
Delivers precise amounts of fast-acting insulin 24/7 by enabling you to set different basal programs. An innovative Bolus Wizard® does the insulin calculations for you to suggest bolus amounts quickly and easily.
The CONTOUR® LINK meter comes free with your pump and links wirelessly to it. The Meter automatically sends your blood glucose results, taking away the need to record your own readings and ensuring greater accuracy.
With CareLink™ personal software you can quickly and easily download your insulin and glucose data from your pump and share it with your doctor in person or remotely. Together, you can refine your diabetes management to optimise your therapy.
In collaboration with the Australian Government, JDRF’s Type 1 Diabetes Insulin Pump Program offers insulin pump subsidies for people under the age of 18, who meet eligibility criteria.
If you don’t meet the criteria for JDRF’s Type 1 Diabetes Insulin Pump Program, you may be eligible for Medtronic’s Patient Assistance Program.
Currently, the Australian Government offers CGM funding to children and young adults under the age of 21, who meet the eligibility criteria for the CGM Initiative. Learn more about the CGM Initiative to discover whether you’re eligible. If you’re not eligible for CGM funding, Medtronic offers a number of subscription packages, including a $50 sensor and transmitter subscription for the MiniMed® Veo™. View CGM Deals.
3. Based on the recommendation insulin pump infusion set change once every 2-3 days compared to 4 injections a day for 30 days.
4. Hermanides J. et al. Sensor-augmented pump therapy lowers HbA1c in suboptimally controlled type 1 diabetes; a randomized controlled trial. Diabetic Medicine. 2011;28(10):1158-67.
5.Bergenstal RM, Tamborlane WV, Ahmann A, et al. Effectiveness of sensor-augmented insulin-pump therapy in type 1 diabetes. NEJM. 2010, Jul 22;363(4):311-20
6.Juvenile Diabetes Research Foundation Continuous Glucose Monitoring Study Group. Sustained Benefits of Continuous Glucose Monitoring through 12 Months of Sensor Use in the JDRF CGM Randomized Clinical Trial. ADA 2009 p. 204-OR.
7. Juvenile Diabetes Research Foundation Continuous Glucose Monitoring Study Group. Sustained Benefits of Continuous Glucose Monitoring on HbA1c, Glucose Profiles, and Hypoglycemia in Adults with Type 1 Diabetes. Diabetes Care. 2009, (32): 2047-2049.
8. Raccah D, Sulmont V, Reznik Y et al. Incremental value of continuous glucose monitoring when starting pump therapy in patients with poorly controlled type 1 diabetes: the Real Trend study. Diabetes Care. 2009, December; 32(12):2245-50.
9. Juvenile Diabetes Research Foundation Continuous Glucose Monitoring Study Group. Continuous glucose monitoring and intensive treatment of type 1 diabetes. 2008, October 2;359(14):1464-76.
10. Deiss D, Bolinder J, Riveline JP et al. Improved glycemic control in poorly controlled patients with type 1 diabetes using real-time continuous glucose monitoring. Diabetes Care. 2006, December; 29(12):2730-2.
11. O’Connell MA, Donath S, O’Neal DN et al. Glycaemic impact of patient-led use of sensor-guided pump therapy in type 1 diabetes: a randomized controlled trial. Diabetologia. 2009, April 25.
12. Bergenstal RM, Klonoff DC, Garg SK, et al. Threshold-Based InsulinPump Interruption for Reduction of Hypoglycemia. NEJM. 2013 June 22. Published ahead of print.
13. Ly TT, et al. Reduction of Severe Hypoglycemia with Sensor-Augmented Insulin Pump Therapy and Automated Insulin Suspension in Patients with Type 1 Diabetes. Abstract and Oral (228-OR) presented at 73rd Scientific Sessions, American Diabetes Association. June 21-25, 2013. Chicago, IL.